Mar. 3rd, 2017. (BUSINESS WIRE) –\u00a0\u00a0Cerveau Technologies, Inc. today announced a clinical research agreement with the University of Wisconsin-Madison Alzheimer’s Disease Research Center to support various research projects studying the stages of Alzheimer’s Disease and other neurodegenerative diseases. These research projects will utilize an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.<\/p>\n
As part of the agreement, Cerveau will provide support for various research projects at the Wisconsin Alzheimer’s Disease Research Center and will supply the MK-6240 precursor needed for the initiatives.
\nDr. Sterling Johnson, Associate Director of the Wisconsin Alzheimer’s Disease Research Center said, “This collaborative tau imaging research program will provide valuable information about the rates of progression across the Alzheimer’s Disease stages from preclinical to overt dementia. We appreciate the support of Cerveau Technologies, Inc.”<\/p>\n
“At Cerveau, we are focused on providing information and technologies to researchers and clinicians to improve brain health,” said Rick Hiatt, President of Cerveau Technologies, Inc., “We are excited by the opportunity to work with the Wisconsin Alzheimer’s Disease Research Center and the pharmaceutical industry to provide access to this novel imaging agent to the broader scientific community.”<\/p>\n
About Cerveau Technologies, Inc.<\/strong> About the Wisconsin Alzheimer’s Disease Research Center<\/strong> Mar. 3rd, 2017. (BUSINESS WIRE) –\u00a0\u00a0Cerveau Technologies, Inc. today announced a clinical research agreement with the University of Wisconsin-Madison Alzheimer’s Disease Research Center to support various research projects studying the stages of Alzheimer’s Disease and other neurodegenerative diseases. These research projects will utilize an early stage imaging agent (MK-6240) to be used in Positron Emission […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[11],"tags":[],"class_list":["post-3779","post","type-post","status-publish","format-standard","hentry","category-company-news"],"meta_box":[],"_links":{"self":[{"href":"https:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/posts\/3779","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/comments?post=3779"}],"version-history":[{"count":1,"href":"https:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/posts\/3779\/revisions"}],"predecessor-version":[{"id":3780,"href":"https:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/posts\/3779\/revisions\/3780"}],"wp:attachment":[{"href":"https:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/media?parent=3779"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/categories?post=3779"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/tags?post=3779"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nCerveau Technologies, Inc. is a partnership between Enigma Biomedical Group, Inc. and Sinotau Pharmaceutical Group. Cerveau’s vision is to globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer’s disease.<\/p>\n
\nThe Wisconsin ADRC is an NIH funded center established in 2009. Its programmatic focus is on preclinical Alzheimer’s Disease. The ADRC conducts clinical and basic science cutting edge research regarding early identification, causes and treatments of Alzheimer’s Disease and related disorders.<\/p>\n","protected":false},"excerpt":{"rendered":"